57 related articles for article (PubMed ID: 38710522)
1. Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer.
Arbyn M; Rousta P; Bruni L; Schollin Ask L; Basu P
J Natl Cancer Inst; 2024 Jun; 116(6):775-778. PubMed ID: 38501990
[No Abstract] [Full Text] [Related]
2. HPV infection: immunological aspects and their utility in future therapy.
Deligeoroglou E; Giannouli A; Athanasopoulos N; Karountzos V; Vatopoulou A; Dimopoulos K; Creatsas G
Infect Dis Obstet Gynecol; 2013; 2013():540850. PubMed ID: 24023507
[TBL] [Abstract][Full Text] [Related]
3. Impact of the human papillomavirus vaccine in low-resource settings.
Murenzi G; Mungo C
Lancet Glob Health; 2023 Jul; 11(7):e997-e998. PubMed ID: 37207682
[No Abstract] [Full Text] [Related]
4. Evolution of Education-Focused Digital Interventions to Support Human Papillomavirus Vaccination.
Real FJ; Meisman A; Fleck L; Klein M; Kahn JA; Rosen BL
Acad Pediatr; 2024; 24(4):559-561. PubMed ID: 37952877
[No Abstract] [Full Text] [Related]
5. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
7. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
8. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
[TBL] [Abstract][Full Text] [Related]
9. [Research progress on the differences between T and B cell responses to three different forms of human papilloma virus (HPV) vaccination].
Peng Q; Li Y; Li J; Yao X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):378-382. PubMed ID: 38710522
[TBL] [Abstract][Full Text] [Related]
10. [Diseases caused by human papilloma viruses].
Zollner U; Schwarz TF
Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
[TBL] [Abstract][Full Text] [Related]
11. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
Du J; Ährlund-Richter A; Näsman A; Dalianis T
Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
